A Pharmacokinetic Comparability Study of a Commercial Supply of Eptinezumab
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2019
Price : $35 *
At a glance
- Drugs Eptinezumab (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Acronyms ALD403-CLIN-014
- 22 Feb 2019 According to an Alder Biopharmaceuticals media release, based on the data from PROMISE 1, PROMISE 2 and an open-label safety study, company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for eptinezumab.
- 23 Oct 2018 Results published in the Alder Biopharmaceuticals Media Release
- 23 Oct 2018 According to an Alder Biopharmaceuticals Media Release,Status changed from planning to completed.